TAXOTERE

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Pieejams no:

SANOFI - AVENTIS ISRAEL LTD

ATĶ kods:

L01CD02

Zāļu forma:

CONCENTRATE FOR SOLUTION FOR INFUSION

Ievadīšanas:

I.V

Ražojis:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Ārstniecības grupa:

DOCETAXEL

Ārstēšanas norādes:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Autorizācija datums:

2012-11-01